Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties (ECLIPSE)

Sanofi

Status and phase: Completed; Phase 3

Conditions: Primary Insomnia

Treatments: Drug: Eplivanserin; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00805350

EFC10844

2008-003791-22 (EudraCT Number)

Details and patient eligibility

About

Primary objective:

• To assess the efficacy of eplivanserin 5mg/day in comparison to placebo after 6 weeks of treatment on sleep maintenance of insomniac patients, as measured by Polysomnography Wake Time After Sleep Onset (PSG-WASO) and Polysomnography Number of Awakenings (PSG-NAW).

Secondary objectives:

• To evaluate the effects of eplivanserin 5mg/day as compared to placebo after 6 weeks of treatment on other sleep parameters measured by PSG recordings (Total Sleep Time - PSG-TST, Sleep Efficiency - PSG-SE, Latency to Persistent Sleep - PSG-LPS) and reported by patients (Wake Time After Sleep Onset - pr-WASO, Number of Awakenings - pr-NAW, Total Sleep Time - pr-TST, Quality of Sleep - QoS and Refreshing Quality of Sleep - RqoS).
• To evaluate the effects of eplivanserin 5mg/day on sleep architecture compared to placebo.
• To evaluate the effect of eplivanserin 5mg/day on daytime functioning using the Sleep Impact Scale (SIS), as compared with placebo after 6 weeks of treatment.
• To evaluate patient's impression of treatment effects using the Patient's Global Impression questionnaire.
• To evaluate the potential for next-day residual effects (using patient's morning questionnaire and psychometric tests) with eplivanserin 5mg/day as compared to placebo.
• To evaluate the potential for rebound insomnia following abrupt discontinuation of eplivanserin 5mg/day in comparison with placebo.
• To evaluate the effect of eplivanserin, compared to placebo, on the quality of life of patients with primary insomnia using the SF-36 Health Survey.
• To evaluate the clinical safety and tolerability of eplivanserin 5mg/day compared to placebo.

Full description

Randomized, double-blind, placebo, controlled study with 2 parallel groups Duration of treatment : 6 weeks

Duration of observation: 9 weeks

Enrollment: 637 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary insomnia based on DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revisions) criteria

Exclusion criteria

• Inpatients.
• Mean screening PSG-WASO for screening night 1+ screening night 2 < 45 mn, or screening night with PSG-WASO < 30 mn.
• Mean screening PSG-TST for screening night 1 + screening night 2 ≥7 hours or ≤3hours.
• Mean screening PSG-LPS for screening night 1+ screening night 2 > 30 mn.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

637 participants in 2 patient groups, including a placebo group

Eplivanserin

Experimental group

Description:

Eplivanserin 5 mg/day

Treatment:

Drug: Eplivanserin

Placebo

Placebo Comparator group

Description:

Placebo of Eplivanserin 5 mg/day

Treatment:

Drug: Placebo